{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:06:01Z","timestamp":1787018761769,"version":"build-2736575974"},"reference-count":35,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>The therapeutic use of psychedelics for mental health issues holds considerable promise. However, systematic assessment of adverse events associated with these substances has received relatively little attention. Here, we discuss several considerations concerning the assessment of adverse events in psychedelic-assisted therapies. We discuss the preference for using the term \u201cadverse effects\u201d over \u201cside effects\u201d, as well as the ongoing debate regarding which substances are classified as psychedelic. We also provide recommendations on when and how to assess adverse effects, for example the importance to study them in any kind of therapy involving psychedelics, and using comprehensive monitoring of a wide range of physical parameters in combination with behavioral outcomes and the individual\u2019s experience, at baseline and throughout the study. Also, sex-specific differences should be considered. Furthermore, we highlight several significant studies that have addressed these aspects. In summary, psychedelics offer great promise as a potential treatment (add-on) option in psychiatry, but more rigorous assessment of adverse effects is needed to promote safe use and implementation in clinical practice.<\/jats:p>","DOI":"10.1177\/02698811251340929","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T03:35:27Z","timestamp":1747798527000},"page":"896-899","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Psychedelic-assisted psychotherapy: The need to monitor adverse events"],"prefix":"10.1177","volume":"39","author":[{"given":"KRJ","family":"Schruers","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Neuropsychology, Mental Health and Neuroscience Research Institute, Maastricht University, Maastricht, The Netherlands"},{"name":"Department of Health Psychology, University of Leuven, Leuven, Belgium"},{"name":"Mondriaan Mental Health Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2347-5423","authenticated-orcid":false,"given":"NK","family":"Leibold","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neuropsychology, Mental Health and Neuroscience Research Institute, Maastricht University, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-022-06123-7"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221116926"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4771-x"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3714-z"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.8b00155"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.55.3.3"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05978-6"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13918"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2022.08.025"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsc.2024.01.007"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10503307.2023.2286992"},{"key":"e_1_3_2_14_1","volume-title":"Chapter 2\u2014Principles of Pharmacodynamics. IN: Forensic Toxicology (Second Edition)","author":"Lappas NT","year":"2022","unstructured":"Lappas NT, Lappas CM (2022) Chapter 2\u2014Principles of Pharmacodynamics. IN: Forensic Toxicology (Second Edition). San Diego, CA: Academic Press."},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000648"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.etdah.2021.100017"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01336-3"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02565-4"},{"key":"e_1_3_2_19_1","unstructured":"Mithoefer MC (2017) A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress DisorderTreatment Manual: MDMA-Assisted Therapy for PTSD (version 8.1). Available at: https:\/\/maps.org\/wp-content\/uploads\/2022\/05\/MDMA-Assisted-Psychotherapy-Treatment-Manual-V8.1-22AUG2017.pdf (accessed 24 September 2024)."},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/13814788.2017.1375091"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.020"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241265756"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0001699320980050"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.35082"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2016_459"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.1c00020"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.12.040"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2014.11.015"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4733-3"},{"key":"e_1_3_2_30_1","article-title":"How to approach the mental state examination","volume":"357","author":"Soltan M","year":"2017","unstructured":"Soltan M, Girguis J (2017) How to approach the mental state examination. BMJ 357: j1821.","journal-title":"BMJ"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117691569"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199812010-00024"},{"key":"e_1_3_2_33_1","volume-title":"Safety of Medicine, A Guide to Detecting and Reporting Adverse Drug Reactions","author":"World Health Organization","year":"2002","unstructured":"World Health Organization (2002) Safety of Medicine, A Guide to Detecting and Reporting Adverse Drug Reactions. Geneva, Switzerland: World Health Organization."},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05692-9"},{"key":"e_1_3_2_35_1","article-title":"Corrigendum to \u201cdecreases in suicidality following psychedelic therapy: A meta-analysis of individual patient data across clinical trials.\u201d","volume":"83","author":"Zeifman RJ","year":"2022","unstructured":"Zeifman RJ, Yu D, Singhal N, et al. (2022a) Corrigendum to \u201cdecreases in suicidality following psychedelic therapy: A meta-analysis of individual patient data across clinical trials.\u201d J Clin Psychiatry 83: 22l14505.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_2_36_1","article-title":"Decreases in suicidality following psychedelic therapy: A meta-analysis of individual patient data across clinical trials","volume":"83","author":"Zeifman RJ","year":"2022","unstructured":"Zeifman RJ, Yu D, Singhal N, et al. (2022b) Decreases in suicidality following psychedelic therapy: A meta-analysis of individual patient data across clinical trials. J Clin Psychiatry 83: 21r14057.","journal-title":"J Clin Psychiatry"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251340929","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251340929","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251340929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:14Z","timestamp":1777507934000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251340929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1177\/02698811251340929"],"URL":"https:\/\/doi.org\/10.1177\/02698811251340929","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]}}}